Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth Crabtree-Hartman

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Continuum (Minneapolis, Minn.)|July 20, 2012
Sex differences in multiple sclerosisElizabeth Crabtree-Hartman
Neurologic Clinics|November 22, 2017
Advanced Symptom Management in Multiple SclerosisElizabeth Crabtree-Hartman
JAMA Neurology|May 3, 2016
Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod TreatmentStacy Ellen Hatcher, Emmanuelle Waubant, Bardia Nourbakhsh, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|February 19, 2019
Clinic to in-home telemedicine reduces barriers to care for patients with MS or other neuroimmunologic conditionsRiley Bove, Priya Garcha, Carolyn J Bevan, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|December 21, 2018
Disease-modifying therapies alter gut microbial composition in MSIlana Katz Sand, Yunjiao Zhu, Achilles Ntranos, et al.
Plos One|February 10, 2011
Switching multiple sclerosis patients with breakthrough disease to second-line therapyTamara Castillo-Trivino, Ellen M Mowry, Alberto Gajofatto, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 13, 2017
Gut bacteria from multiple sclerosis patients modulate human T cells and exacerbate symptoms in mouse modelsEgle Cekanaviciute, Bryan B Yoo, Tessel F Runia, et al.
Annals of Neurology|September 30, 2014
Precision medicine in chronic disease management: The multiple sclerosis BioScreenPierre-Antoine Gourraud, Roland G Henry, Bruce A C Cree, et al.
Annals of Neurology|July 28, 2016
Long-term evolution of multiple sclerosis disability in the treatment era, Bruce A C Cree, Pierre-Antoine Gourraud, et al.
Annals of Neurology|March 2, 2022
Reply to "Spinal Cord Atrophy Is a Preclinical Marker of Progressive MS"Antje Bischof, Nico Papinutto, Anisha Keshavan, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Continuum (Minneapolis, Minn.)|July 20, 2012
Sex differences in multiple sclerosisElizabeth Crabtree-Hartman
Neurologic Clinics|November 22, 2017
Advanced Symptom Management in Multiple SclerosisElizabeth Crabtree-Hartman
JAMA Neurology|May 3, 2016
Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod TreatmentStacy Ellen Hatcher, Emmanuelle Waubant, Bardia Nourbakhsh, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|February 19, 2019
Clinic to in-home telemedicine reduces barriers to care for patients with MS or other neuroimmunologic conditionsRiley Bove, Priya Garcha, Carolyn J Bevan, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|December 21, 2018
Disease-modifying therapies alter gut microbial composition in MSIlana Katz Sand, Yunjiao Zhu, Achilles Ntranos, et al.
Plos One|February 10, 2011
Switching multiple sclerosis patients with breakthrough disease to second-line therapyTamara Castillo-Trivino, Ellen M Mowry, Alberto Gajofatto, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 13, 2017
Gut bacteria from multiple sclerosis patients modulate human T cells and exacerbate symptoms in mouse modelsEgle Cekanaviciute, Bryan B Yoo, Tessel F Runia, et al.
Annals of Neurology|September 30, 2014
Precision medicine in chronic disease management: The multiple sclerosis BioScreenPierre-Antoine Gourraud, Roland G Henry, Bruce A C Cree, et al.
Annals of Neurology|July 28, 2016
Long-term evolution of multiple sclerosis disability in the treatment era, Bruce A C Cree, Pierre-Antoine Gourraud, et al.
Annals of Neurology|March 2, 2022
Reply to "Spinal Cord Atrophy Is a Preclinical Marker of Progressive MS"Antje Bischof, Nico Papinutto, Anisha Keshavan, et al.
Pageof 1